Effects of Omega-3 Fatty Acids on Markers of Inflammation in Patients With Chronic Kidney Disease: A Controversial Issue.
Effects of Omega-3 Fatty Acids on Markers of Inflammation in Patients With Chronic Kidney Disease: A Controversial Issue.
复制标题
Omega-3 脂肪酸对慢性肾病患者炎症标志物的影响：一个有争议的问题。
DOI：
10.1111/1744-9987.12611
复制
发表时间：
2018-04
期刊：
影响因子：
--
通讯作者：
Sun L
中科院分区：
文献类型：
--
作者：
Hu C;Yang M;Zhu X;Gao P;Yang S;Han Y;Chen X;Xiao L;Yuan S;Liu F;Kanwar YS;Sun L
慢性肾脏病（CKD）是一个全球性的问题，在中国的发病率和死亡率都很高。伴随的炎症状态进一步增加了接受透析的CKD患者的心血管事件死亡率。一般认为，欧米茄-3脂肪酸，包括二十二碳六烯酸（DHA）和二十碳五烯酸（EPA），可能通过调节炎症而具有一定的健康益处。然而，omega-3脂肪酸在CKD患者中的抗炎作用存在争议。我们通过检索数据库中从开始到2016年8月的文献，分析了CKD患者口服补充omega-3脂肪酸的数据。该分析包括来自多个数据库的随机对照试验（RCT），并比较了omega-3脂肪酸补充剂与对照组的效果。所有数据分析均采用RevMan 5.2进行计算。共纳入12项RCT，涉及487例患者。其中254名患者接受omega-3脂肪酸治疗，233名患者接受安慰剂治疗作为对照。荟萃分析显示，血清CRP水平无统计学意义（SMD，−0.20; 95% CI，−0.44至0.05; p=0.11），IL-6（SMD，0.00; 95%CI，−0.33至0.33; p=0.99）和TNF-α（SMD，0.14; 95%CI，−0.17至0.44; p=0.38）之间的ω-3脂肪酸补充组和对照组。这表明，没有足够的证据得出结论，认为口服补充omega-3脂肪酸可降低CKD患者的CRP、IL-6和TNF-α血清水平。
Chronic kidney disease (CKD) is a global problem, which contributes to a significant morbidity and mortality in China. Concomitant inflammatory state further boosts the mortality due to cardiovascular events in patients with CKD undergoing dialysis. There is a general notion that Omega-3 fatty acid including, docosahexaenoic acids (DHA) and eicosapentaenoic (EPA) has certain health benefits perhaps via the regulation of inflammation. However, the anti-inflammatory effect of omega-3 fatty acids in patients with CKD is controversial. We analyzed the data of oral supplementation of omega-3 fatty acid in CKD patients by searching literature on database from inception to August 2016. The analysis included randomized controlled trials (RCTs) derived from multiple databases, and the effect of omega-3 fatty acids supplementation versus the control cohorts were compared. All of the data analysis was calculated by RevMan 5.2. A total of twelve RCTs involving 487 patients were included in the meta-analysis. Among them 254 patients received omega-3 fatty acid and 233 patients served as controls who received placebo. The meta-analysis revealed no statistical significance in serum levels of CRP (SMD, −0.20; 95% CI, −0.44 to 0.05; p=0.11), IL-6 (SMD, 0.00; 95% CI, −0.33 to 0.33; p=0.99) and TNF-α (SMD, 0.14; 95% CI, −0.17 to 0.44; p=0.38) between the omega-3 fatty acids supplementation group and control. This suggested that there is insufficient evidence to conclude the benefit of omega-3 fatty acids oral supplementation in reducing serum levels of CRP, IL-6 and TNF-α in patients with CKD.
登录
查看更多内容
影响因子：
39.2
作者：
KREMER, JM;JUBIZ, W;LININGER, L
通讯作者：
LININGER, L
影响因子：
13.2
作者：
Bologa, RM;Levine, DM;Rubin, AL
通讯作者：
Rubin, AL
DOI：
10.2215/cjn.04150415
发表时间：
2016-07-01
影响因子：
9.8
作者：
Deger, Serpil Muge;Hung, Adriana M.;Ikizler, T. Alp
通讯作者：
Ikizler, T. Alp
影响因子：
19.6
作者：
HERBELIN, A;URENA, P;DESCAMPSLATSCHA, B
通讯作者：
DESCAMPSLATSCHA, B
影响因子：
5.8
作者：
Ferrucci, L;Cherubini, A;Guralnik, JM
通讯作者：
Guralnik, JM